Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04054999 · ClinicalTrials.gov registry record · Phase 4

Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients

A Phase 4 study, sponsored by Mayo Clinic.

Completed
Registry status
Phase 4
Development phase
19
Enrollment target

NCT04054999: Completed Phase 4 study, sponsored by Mayo Clinic.

NCT04054999 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 19 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04054999, a Phase 4 study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 4
Development phase
19 participants
Enrollment target

Study Summary

This study will evaluate if Hydroxocobalamin may be a new and possibly superior treatment for refractory vasoplegic syndrome during liver transplant surgery.

Primary Outcome

SVR refers to the resistance to blood flow offered by all of the systemic vasculature, excluding the pulmonary vasculature. Measured during surgery at 15, 30, 60, 90 and 120 minutes after initiation of treatment.

Interventions

  • DRUG Hydroxocobalamin
  • DRUG Methylene Blue

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2019-11-30
Est. Completion 2024-02-27
Phase Phase 4
Mayo Clinic

2,844 total trials

What the finished NCT04054999 record still lists

NCT04054999 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 2 interventions - of which Hydroxocobalamin is the first listed.

NCT04054999 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04054999 about?

NCT04054999 is a clinical study titled "Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients". This study will evaluate if Hydroxocobalamin may be a new and possibly superior treatment for refractory vasoplegic syndrome during liver transplant surgery.

What is the current status of trial NCT04054999?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2019-11-30. Estimated completion is 2024-02-27.

What interventions are being tested in trial NCT04054999?

The interventions under investigation include: Hydroxocobalamin (DRUG), Methylene Blue (DRUG).

Who is sponsoring clinical trial NCT04054999?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04054999's enrollment target sits among peer trials

19 1834th of 2000 higher than 159 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03207464 · 19 participants · Phase 1

    Molecular Imaging of NET Using [C-11]MRB-PET in MS

  • NCT04318717 · 19 participants · Phase 2

    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  • NCT05103904 · 19 participants · Phase 2

    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  • NCT05607407 · 19 participants · Phase 2

    Methimazole in Patients With Progressive Glioblastoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04054999, the US trial registry maintained by the National Library of Medicine. NCT04054999 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.